차세대 당뇨병 치료 약물전달 시장 : 규모, 점유율, 성장 분석, 제품별, 인구통계별, 적응증별, 최종 사용자별, 지역별, 업계 예측(2025-2032년)

Global Next Generation Diabetes Therapy Drug Delivery Market size was valued at USD 36.3 billion in 2023 and is poised to grow from USD 39.31 billion in 2024 to USD 74.4 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global market for next generation diabetes therapy and drug delivery is experiencing significant growth, primarily fueled by the rising prevalence of diabetes worldwide. There is a substantial demand for more effective, user-friendly, and minimally invasive treatment options. The focus is shifting from merely managing glucose levels to developing therapies that promote weight loss, enhance cardiovascular health, and ultimately improve patients' quality of life, leading to heightened research and development efforts and market expansion. However, the analysis reveals considerable challenges, including high costs for innovative therapies and devices, which impede reimbursement and access. Additionally, lengthy and expensive regulatory approval processes, coupled with technical hurdles in creating reliable non-invasive systems and fully automated "closed-loop" management, pose significant barriers to future growth in the market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Next Generation Diabetes Therapy Drug Delivery market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Next Generation Diabetes Therapy Drug Delivery Market Segments Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market is segmented by Product, Demographic, Indication, End User and region. Based on Product, the market is segmented into Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas. Based on Demographic, the market is segmented into Adult Population (>14years) and Child Population (14years). Based on Indication, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. Based on End User, the market is segmented into Diagnostic/Clinics, ICUs and Home Healthcare. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Next Generation Diabetes Therapy Drug Delivery Market

The remarkable expansion of the global next generation diabetes therapy drug delivery market is primarily driven by the continuous increase in the prevalence of Type 1 and Type 2 diabetes. This growing population of individuals requiring effective management options highlights a significant demand for innovative and convenient therapeutic solutions. As more people are diagnosed, the need for advanced drug delivery systems that cater to their diverse healthcare needs becomes critical, further fueling the market's growth. Enhanced treatment alternatives not only aim to improve patient outcomes but also strive to simplify the management of diabetes, thereby addressing an ever-expanding market opportunity.

Restraints in the Global Next Generation Diabetes Therapy Drug Delivery Market

One of the significant challenges facing the Global Next Generation Diabetes Therapy Drug Delivery market is the high cost associated with these advanced therapies and devices, which often surpasses the financial capabilities of many patients. This economic burden makes it difficult for individuals to afford necessary treatments. Additionally, obtaining reimbursement from both public and private insurers poses a substantial hurdle, further limiting patient access to these crucial therapies, particularly in emerging markets where healthcare resources may be more constrained. Addressing these financial barriers is essential to ensuring broader accessibility and adoption of innovative diabetes treatments.

Market Trends of the Global Next Generation Diabetes Therapy Drug Delivery Market

The global next generation diabetes therapy drug delivery market is increasingly driven by the demand for interoperability and connectivity among devices. Patients are seeking personalized solutions that enable them to integrate their continuous glucose monitors (CGMs) with insulin pumps, fostering a trend towards open-protocol systems. This shift is not only enhancing patient autonomy but also optimizing diabetes management by facilitating seamless data exchange. As manufacturers respond to this consumer-driven demand, we can anticipate innovative drug delivery systems that prioritize user-friendly applications, increased data accessibility, and improved therapeutic outcomes, ultimately shaping a more interconnected landscape in diabetes care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Product & CAGR (2025-2032)

• Market Overview
• Inhalable Insulin
• Oral Insulin
• Insulin Patches
• CGM Systems
• Artificial Pancreas

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Demographic & CAGR (2025-2032)

• Market Overview
• Adult Population (>14years)
• Child Population (14years)

Global Next Generation Diabetes Therapy Drug Delivery Market Size by Indication & CAGR (2025-2032)

• Market Overview
• Type 1 Diabetes
• Type 2 Diabetes

Global Next Generation Diabetes Therapy Drug Delivery Market Size by End User & CAGR (2025-2032)

• Market Overview
• Diagnostic/Clinics
• ICUs
• Home Healthcare

Global Next Generation Diabetes Therapy Drug Delivery Market Size & CAGR (2025-2032)

• North America (Product, Demographic, Indication, End User)
  • US
  • Canada
• Europe (Product, Demographic, Indication, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Demographic, Indication, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Demographic, Indication, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Demographic, Indication, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Novo Nordisk A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic Plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dexcom, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tandem Diabetes Care, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MannKind Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (BD) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ypsomed AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Senseonics Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Diabeloop SAS (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beta Bionics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Embecta Corp. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biocon Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nemaura Medical Inc. (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations